Abnormal cyanide metabolism in uraemic patients

被引:46
作者
Koyama, K
Yoshida, A
Takeda, A
Morozumi, K
Fujinami, T
Tanaka, N
机构
[1] NAGOYA CITY UNIV, SCH MED, DEPT INTERNAL MED 3, NAGOYA, AICHI 467, JAPAN
[2] JIKEIKAI UNIV, SCH MED, AOTO HOSP, DEPT INTERNAL MED, TOKYO, JAPAN
关键词
chronic renal failure; uraemic neuropathy; cyanide; vitamin B-12; haemodialysis;
D O I
10.1093/ndt/12.8.1622
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. We previously investigated the factors involved in uraemic neuropathy in patients undergoing regular haemodialysis and found a significant relationship between the severity of vibration sensation impairment and the patients' smoking habits. The administration of methylcobalamin markedly improved the severity of uraemic neuropathy in terms of vibration perception thresholds. We presumed that abnormal cyanide metabolism is involved in the development of uraemic neuropathy. Methods. Serum levels of thiocyanate (SCN-), the detoxication product of cyanide, were determined in 12 patients with preterminal chronic renal failure (PCRF), 30 patients undergoing regular haemodialysis (HD patients), and 13 healthy volunteers as a control group, Nine of the 30 HD patients were smokers, In addition, in 10 HD patients without smoking habits and 10 non-smoking healthy volunteers? the proportion of each vitamin B-12 analogue in total vitamin B-12 was estimated. Results. The mean serum SCN-level of the 12 PCRF patients (5.1 +/- 1.5 mu g/ml) was significantly higher than that of the control (2.8 +/- 0.9 mu g/ml) (P<0.01). The mean SCN-level before haemodialysis in the 21 nonsmoking HD patients was identical to that in the PCRF group, whereas the level in the nine smoking HD patients (7.2 +/- 1.8 mu g/ml) significantly higher than that in the non-smoking subgroup (P<0.01). In 16 HD patients with methylcobalamin treatment, serum SCN-levels were lower than in those without methylcobalamin treatment (4.5+/-0.5 mu g/ml in non-smoking subgroup: P<0.05). And in the methylcobalamin-treated subgroup (n=5), the proportion of each vitamin B-12 analogue in total vitamin B-12 was normal. In the untreated subgroup (n=5), the proportion of cyanocobalamin fraction (10.5+/-2.6%) was as high as the level in Leber's disease patients, while the proportion of methylcobalamin fraction was low. And the serum cyanocobalamin level was higher in the treated subgroup. Conclusion. In uraemic patients, cyanide detoxication capability is impaired because of a reduced SCN- clearance, and increased cyanocobalamin synthesis indicates elevation of cyanide pool, which would be related to the development of uraemic neuropathy, Methylcobalamin was considered to be utilized in cyanide detoxication process via cyanocobalamin synthesis.
引用
收藏
页码:1622 / 1628
页数:7
相关论文
共 18 条
[1]  
ASBURY AK, 1984, PERIPHERAL NEUROPATH, P1811
[2]   SEARCH FOR UREMIC TOXIN - DECREASED MOTOR-NERVE CONDUCTION-VELOCITY AND ELEVATED PARATHYROID-HORMONE IN UREMIA [J].
AVRAM, MM ;
FEINFELD, DA ;
HUATUCO, AH .
NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (18) :1000-1003
[3]   The determination of thiocyanate in blood serum [J].
Bowler, RG .
BIOCHEMICAL JOURNAL, 1944, 38 :385-388
[4]   STUDIES ON THE METABOLISM OF THE CARBON OF CYANIDE AND THIOCYANATE [J].
BOXER, GE ;
RICKARDS, JC .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1952, 39 (01) :7-26
[5]  
CLEMENTS RS, 1973, LANCET, V1, P1137
[6]   GUANIDINOSUCCINIC ACIDURIA IN UREMIA - A POSSIBLE ALTERNATE PATHWAY FOR UREA SYNTHESIS [J].
COHEN, BD ;
STEIN, IM ;
BONAS, JE .
AMERICAN JOURNAL OF MEDICINE, 1968, 45 (01) :63-&
[7]  
DYCK PJ, 1971, MAYO CLIN PROC, V46, P400
[8]  
FELDSTEIN M, 1954, J LAB CLIN MED, V44, P166
[9]   DOPAMINERGIC NEUROTOXICITY OF CYANIDE - NEUROCHEMICAL, HISTOLOGICAL, AND BEHAVIORAL CHARACTERIZATION [J].
KANTHASAMY, AG ;
BOROWITZ, JL ;
PAVLAKOVIC, G ;
ISOM, GE .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1994, 126 (01) :156-163
[10]   Efficacy of methylcobalamin in subclinical uraemic neuropathy as detected by measuring vibration perception thresholds [J].
Koyama, K ;
Yoshida, A ;
Takeda, A ;
Morozumi, K ;
Fujinami, T .
NEPHROLOGY, 1996, 2 (01) :25-28